Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intradigm appoints new CEO

This article was originally published in Scrip

Executive Summary

Intradigm (US) has appointed its vice-president of business development, Dr Philip Haworth, as chief executive officer. He succeeds Dr Mohammad Azab, who has resigned as CEO but will retain his position on the company's board of directors.

You may also be interested in...



Reckitt Spies Opportunity For Global Supplements Business

RB CEO Laxman Narasimhan sees the potential for the company to establish a global supplements business built on the successes it has enjoyed in the US and China. The comments came as RB reported solid growth in the third quarter, despite struggles for its OTC brands.

Managing The Expansion of Clinical Trial Data Sources

Increases in remote patient monitoring and decentralized clinical trials – accelerated by COVID-19 – have added complexity to data management systems. Traditional platforms and electronic data capture used by drug development sponsors are ineffectual tools for integrating new primary data sources, or managing remote patient monitoring, Raj Indupuri, CEO at eClinical Solutions told In Vivo. 

Digital Acceleration: Low-Hanging Fruit And Stretch Goals

COVID-19 has pushed the entire health care system to adopt new technologies and new solutions for conducting clinical research and delivering care to patients. An expert panel hosted by the Galien Foundation provided a meditation on what the biopharma industry has learned so far, and how to use the urgency created by COVID-19 to lock-in technological acceleration while maintaining what FDA’s Amy Abernethy called  “responsible progress.”

Topics

UsernamePublicRestriction

Register

SC143162

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel